Context: Dhillon, S.S., Groman, A., Meagher, A., Demmy, T., Warren, G.W., and Yendamuri, S. (2014). Perioperative use of statins in elective colectomy. Care has been taken to select relevant articles supporting the off-label use of these medicines in a clinical setting for the adjunct treatment of cancer. This article does not purport to be a comprehensive review of all the evidence, nor does it capture all of the potential side-effects of such treatment. Results for metformin use in early-stage lung cancer are based on recent population analyses, and prospective trials are required. Gynecol. Statins as anti-cancer therapy; Can we translate preclinical and epidemiologic data into clinical benefit? (2013). Markers for actively dividing cells in the lining of the bowel were also decreased in patients taking metformin. Hadad, S., Iwamoto, T., Jordan, L., Purdie, C., Bray, S., Baker, L., Jellema, G., Deharo, S., Hardie, D.G., Pusztai, L., et al. endstream endobj startxref Nayan, M., Finelli, A., Jewett, M.A.S., Juurlink, D.N., Austin, P.C., Kulkarni, G.S., and Hamilton, R.J. (2017). A trend towards reduced blood levels of PSA was also noted. J Clin Oncol 27, 3297–3302. hެ�[pU��.�tw�\6a This article is for information purposes only and it does NOT constitute medical advice. In this study men with localised prostate cancer who had elected to undergo radical prostatectomy were treated with metformin from the time of their decision up to the point of surgery. Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer. Introduction – page 2 . In the patients who had diabetes, rate of pathologic complete response was 24% for metformin group (n=64) vs. 8.0% in the non-metformin group (n=87). Statement is quoted from findings that were presented during the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting. The effect of metformin on apoptosis in a breast cancer presurgical trial. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. J Cancer Ther 8, 73–85. The impact of metformin use on survival in kidney cancer patients with diabetes: a meta-analysis. hެͻ BQ���s}"��a`�؈�V�`f���.41��ʯg�L>�ew6�4T��#����6��ǹ���[v�L������\�t��-���Nv=�Ʈ�����|sKs�o�+���So���m���Z:} ��� Statin Use in Prostate Cancer: An Update. One population study showed that in men who had been diagnosed with prostate cancer and were presenting for radiation therapy, PSA levels was 20% lower for statin users (p = 0.002) and 33% lower for metformin users (p = 0.004), compared with men who were not on these medications (Liu et al., 2017). BCCCNP MEDICAL PROTOCOL 1 . Chae, Y.K., Yousaf, M., Malecek, M.-K., Carneiro, B., Chandra, S., Kaplan, J., Kalyan, A., Sassano, A., Platanias, L.C., and Giles, F. (2015). Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. In contrast, a Canadian population-based study in 613 patients with newly diagnosed diabetes and a ‘subsequent diagnosis’ of kidney cancer found survival of these patients was not associated with metformin or NSAID use, but was associated with statin use (Nayan et al., 2016). Cheng, J.J.S., Li, H., Tan, H.S., Tan, P.H., Ng, L.G., Ng, Q.S., Toh, C.K., Kanesvaran, R., and Tan, M.-H. (2016). Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer. I’m not a medical professional and no information found here should be considered medical advice. The effects of metformin and statins on the prognosis of earlier-stage kidney cancer patients with diabetes are inconclusive, and more studies are needed. Cazzaniga, M., DeCensi, A., Pruneri, G., Puntoni, M., Bottiglieri, L., Varricchio, C., Guerrieri-Gonzaga, A., Gentilini, O.D., Pagani, G., Dell’Orto, P., et al. %PDF-1.5 %���� (2012). 26, 858–865. In this study metformin was given alongside the standard therapy of medroxyprogesterone acetate (MPA), and metformin therapy was continued after MPA treatment had stopped up until conception or disease recurrence. II. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Br J Cancer 109, 2792–2797. Statin and Metformin Use Prolongs Survival in Patients With Resectable Pancreatic Cancer. Care Oncology doctors will discuss the suitability of these medicines with you and will liaise with your doctor or oncologist to discuss their suitability for you. (Dhillon et al., 2014). Kalinsky, K., Crew, K.D., Refice, S., Xiao, T., Wang, A., Feldman, S.M., Taback, B., Ahmad, A., Cremers, S., Hibshoosh, H., et al. A total of 53 patients were diabetic, including 21 metformin users and 32 non-metformin users. A retrospective analysis investigating the association of diabetes and metformin with survival in 409 patients (including 71 who were diabetic and 41 who used metformin) undergoing resection of stage I non-small cell lung cancer (NSCLC) found that metformin (but not diabetes) use was associated with improved overall survival. Clinical Genitourinary Cancer 15, 300–305. In these studies, there was a trend towards improved recurrence free survival with metformin, but no change in overall survival and cancer specific survival was noted. The authors state that this finding supports initiation of a full randomised trial to investigate whether it is beneficial to start kidney cancer patients on statins at the time of diagnosis. 125, 477–482. Within this context, several studies have investigated the use of one or more of the COC Protocol medications alongside or immediately prior to these standard curative treatments. In addition, a meta-analysis of existing population studies (which included the three above) of 254,329 kidney cancer patients also found association between the use of metformin and improved overall survival and cancer-specific survival. In another interesting pilot study, Hosono et al, (2010) set out to evaluate whether metformin could help supress aberrant crypt foci, one of the earliest changes detected in the bowel which may lead to bowel cancer. 207, 266.e1-12. Babcook, M.A., Joshi, A., Montellano, J.A., Shankar, E., and Gupta, S. (2016). Some of these studies are also outlined below. This combined with a known link between endometrial cancer and insulin resistance in some patient groups has led to a number of small studies investigating metformin as a treatment option for early-stage endometrial cancer. Similar to both breast cancer and prostate cancer, small clinical studies have provided convincing evidence that metformin has potentially beneficial anticancer activity in women with early stage endometrial cancer awaiting surgery. Metformin use was independently predictive of complete response (odds ratio, 2.95; P=0.04) after adjustment for diabetes, body mass index, age, stage, grade, receptor status, and neoadjuvant taxane use. Two recent population studies showed no survival benefit for patients who were taking metformin at the time of cancer diagnosis or surgery (Nayan et al., 2016, 2017). TABLE OF CONTENTS . Other studies have also reported similar potentially beneficial changes to cancer cell markers and cancer-related gene expression in patients who took metformin or statins while waiting for surgery (Hadad et al., 2011, Bjarnadottir et al., 2013). 612 0 obj <> endobj They went on to call for the proper evaluation of these findings and of the potential survival benefits of metformin in this population using randomised trials (Niraula et al., 2012). "COC Protocol" and "Care Oncology" and the "flame" icon are registered trademarks by Care Oncology LLC. Bonanni, B., Puntoni, M., Cazzaniga, M., Pruneri, G., Serrano, D., Guerrieri-Gonzaga, A., Gennari, A., Trabacca, M.S., Galimberti, V., Veronesi, P., et al. Radiother Oncol 118, 453–459. Oncol. In these studies, women with operable endometrial cancer who took metformin in the weeks preceding surgery had encouraging changes in various cell markers associated with cancer cell division and growth, suggesting that metformin inhibited cancer cell growth in these women (Mitsuhashi, 2014; Laskov, 2014, Schuler et al., 2015). Biological marker evidence from a small prospective study (Joshua et al., 2014) is supportive of the above findings. Metformin and Not Diabetes Influences the Survival of Resected Early Stage NSCLC Patients. (2012). 1 . Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. (2016). Treat. Colon Rectum 55, 205–210. The Care Oncology (“COC”) Protocol is protected by United States patent US9622982B2 and by various additional international patents. Pancreas 45, 64–70. Interestingly, the benefits in survival noted with statin use in this population was not associated with cumulative use, but with ‘active’ use, meaning that the length of time the patient had been taking statins prior to or after diagnosis had no bearing on their survival. "Patient survivability doubled." Cancer Med 4, 161–173. Read 1 Responses. (2014). When adding codes for an operation check for the diagnosis Several prospective studies have generated data which potentially supports the use of metformin and statins in patients with early-stage or newly diagnosed breast cancer. �{̯����,�Ո)i��3^H]�|J�sIK�Q��'=�����_^�li�Kּ����+��ˊ���Wm%�+WI���(_c����_�]���a�͆�����薷��������m�ڶ�n~��������{v�����o���]����Ї�|p���n$�ZF��>�w��G=�. Prostate Cancer and Prostatic Diseases 17, 252–258. (2015). In one pre-surgical study in patients with newly diagnosed non-diabetic breast cancer, 39 patients received metformin in the time period from diagnostic biopsy to surgery (median 18 days). 134, 607–614. And in a similar (though smaller) retrospective study which investigated survival outcomes in 40 diabetic patients with locally-advanced, inoperable NSCLC treated with definitive chemoradiation found no significant difference or numerical trend in overall survival, progression-free survival, locoregional recurrence-free survival or distant metastasis-free survival (Ahmed et al, 2015). J. Clin. 0 Receive and implement your personalized protocol that works in addition to (not instead of) standard oncology treatment. Clinical Genitourinary Cancer 14, 168–175. Metformin Suppresses Colorectal Aberrant Crypt Foci in a Short-term Clinical Trial. Cancer Register – newly diagnosed after 1/4/03 . Journal of Thoracic Disease 7, 346–355. The medicines discussed herein are available on prescription-only and should not be taken without consultation with your doctor or other professional healthcare provider. Patients on statins had a reduced risk of death from any cause, and also from kidney cancer (adjusted hazard ratio 0.71; 95% CI 0.51–0.97). The researchers suggest that this study provides preliminary evidence that metformin can potentially suppress early markers of bowel cancer in humans. My question is it not the medical communities protocol for cancer screenings to be conducted where cancer is present or found in a person's body that has been subsequently removed? BCCCNP Age and Insurance Eligibility to Receive Breast and Cervical Cancer Screening and/or Beneficial shifts in lipid and glycogen metabolism and circulating metabolic factors were also noted, and associated with a better response in some patients (Schuler et al., 2015, Mitsuhashi et al., 2014). Breast Cancer Res Treat 128, 783–794. Statement is based on the results of a 95-patient cohort phase-3 clinical trial of COC Protocol with patients diagnosed with glioblastoma multiforme. Kozak, M.M., Anderson, E.M., Eyben, R. von, Pai, J.S., Poultsides, G.A., Visser, B.C., Norton, J.A., Koong, A.C., and Chang, D.T. Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer. J. Obstet. The COC study is filed in the UK under the title: Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer (METRICS) ClinicalTrials.gov Identifier: NCT02201381. h�bbd```b``�"׀H� �=D2��e������`q0) &��eO ��� 2�)�-6�,�m"ʀ$c+�� "�c@��0l�w0�&�@d�~0�H��-b`bd`W���8`���]� ��� However, in Cheng et al (2016), a retrospective analysis of 390 kidney cancer patients with diabetes (of which 290 had localised disease), metformin users with localised kidney cancer had significantly better disease free survival and cancer-specific survival than non-users. Population studies for metformin use in earlier stage prostate cancer are mixed, but overall appear promising. Wink, K.C.J., Belderbos, J.S.A., Dieleman, E.M.T., Rossi, M., Rasch, C.R.N., Damhuis, R.A.M., Houben, R.M.A., and Troost, E.G.C. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial. (2014). 138, 499–508. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. This article outlines some of the evidence supporting the use of COC Protocol medications in earlier stage cancer. Jiralerspong, S., Palla, S.L., Giordano, S.H., Meric-Bernstam, F., Liedtke, C., Barnett, C.M., Hsu, L., Hung, M.-C., Hortobagyi, G.N., and Gonzalez-Angulo, A.M. (2009). Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. There is obviously a need for finding ways to reduce the recurrence rate of endometrial cancer in women who wish to go on to conceive. 32, 150–157. "May halve the risk of dying from cancer" Liu, X., Li, J., Schild, S.E., Schild, M.H., Wong, W., Vora, S., Herman, M.G., and Fatyga, M. (2017). 646 0 obj <>/Filter/FlateDecode/ID[]/Index[612 49]/Info 611 0 R/Length 139/Prev 805467/Root 613 0 R/Size 661/Type/XRef/W[1 3 1]>>stream Importantly, metformin appears to be more effective in some patients compared to others, with metabolic characteristics such as insulin resistance implicated. This is because early‑stage cancers are generally smaller and more localised to one place in the body. For example, disease response and metformin intake was investigated in a retrospective population study of 2,529 patients who received neoadjuvant chemotherapy for early-stage breast cancer between 1990 and 2007 (Jiralerspong et al., 2009). Hosono, K., Endo, H., Takahashi, H., Sugiyama, M., Sakai, E., Uchiyama, T., Suzuki, K., Iida, H., Sakamoto, Y., Yoneda, K., et al. Metformin significantly reduced Ki67, a molecular marker used to measure the presence of fast dividing cells (proliferation), which is characteristic of cancer cells. %%EOF This article is an overview of some of the scientific and medical published literature concerning the medications which comprise the patented Care Oncology protocol. 1 Responses MEDICAL PROFESSIONAL Kamal S Saini, MD, MRCP (UK), DM. For this reason they tend to be easier and more successful to treat. The ESMO Clinical Practice Guidelines on Breast Cancer cover primary breast cancer and include information on staging and diagnosis, treatment and follow-up. In comparison to advanced cancers which have spread, the standard treatment approach for early-stage cancers is more often intended as a cure, and prevention of recurrence. Home » The COC Protocol™ in Early-Stage Cancer. Li, Y., Hu, L., Xia, Q., Yuan, Y., and Mi, Y. Bjarnadottir, O., Romero, Q., Bendahl, P.-O., Jirström, K., Rydén, L., Loman, N., Uhlén, M., Johannesson, H., Rose, C., Grabau, D., et al. Laskov, I., Drudi, L., Beauchamp, M.-C., Yasmeen, A., Ferenczy, A., Pollak, M., and Gotlieb, W.H. Progestin therapy is often used as a fertility-sparing treatment for patients with endometrial cancer or atypical endometrial hyperplasia (AEH). Gallos, I.D., Yap, J., Rajkhowa, M., Luesley, D.M., Coomarasamy, A., and Gupta, J.K. (2012). The researchers found that patients who took statins or metformin had better overall survival compared to those that did not. What this means in the context of early-stage kidney cancer therefore requires further investigation. Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. Cell Cycle 16, 737–745. Cancer Prev Res 3, 1077–1083. In this study, metformin use was an important predictor of good survival in multivariate analysis (hazard ratio=3.08; P<0.01) after adjusting for age, gender, pathologic stage, histology and smoking status. (2016). BCCCNP Clinical Services Provided to Eligible Clients - page 3 . It is evident that the time is now ripe for more major studies into the clinical benefits of adjuvant use of metformin and other COC Protocol medications in early-stage disease. Gynecol. Hepatol. If you think you may be suffering from any medical condition you should seek immediate medical attention. Hi, I am sorry to hear of your mothers history and outcome. In the meta-analysis of retrospective studies conducted by Coyle et al (2016), 3 studies including 2045 patients were analysed. Cancer Invest. 0 Follow - 0. 30, 2593–2600. Ann Oncol 27, 262–266. Impact of metformin use on survival in locally-advanced, inoperable non-small cell lung cancer treated with definitive chemoradiation. Am. Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer. Much of this evidence is for metformin, and statins, and many of these studies take the form of retrospective and observational population studies in patients with or without diabetes. CHD (any date) & LVD since 1/4/03 . Niraula, S., Dowling, R.J.O., Ennis, M., Chang, M.C., Done, S.J., Hood, N., Escallon, J., Leong, W.L., McCready, D.R., Reedijk, M., et al. For example, a major 2016 meta-analysis of adjuvant metformin use in early-stage cancer identified 23 publications and 4 conference abstracts which assessed survival outcomes in this context (Coyle et al., 2016). (2013). Chen, T.-M., Lin, C.-C., Huang, P.-T., and Wen, C.-F. (2011). Gynecol. Summing up these findings, the researchers concluded ‘short-term preoperative metformin was well tolerated and resulted in clinical and cellular changes consistent with beneficial anti-cancer effects’. Ahmed, I., Ferro, A., Cohler, A., Langenfeld, J., Surakanti, S.G., Aisner, J., Zou, W., Haffty, B.G., and Jabbour, S.K. (2016). The findings of this study were broadly positive, particularly for prostate cancer and bowel cancer, and are discussed in more detail below. Dis. Use of both metformin and statins have been associated with lower prostate serum antigen (PSA) levels (and therefore potentially less advanced disease) in observational studies of men with newly diagnosed prostate cancer (Babcook et al, 2016). COC Protocol is offered as an adjunctive therapy for conventional cancer therapies. h�b```��B cc`a��$� h���7�VP�9�iց�4V��Lq/0>�kȨq`G�� ���%h�p�3�9pYA%��i�Ki��-�� �jrGMc@�3e.�.-��i(����c����+���\78�p��z9P50��q��B�a?_���]��F�\��抂�M�=��&:�\��#�L��hN���/ĺ��(����`�c��%��r�[��%25M��K#M&d. I. In particular, patients with localised, early-stage disease appeared to benefit from metformin use (OS: HR 0.634, 95% CI 0.440–0.913, P = 0.014; CSS: HR 0.476, 95% CI 0.295– 0.768, P = 0.002) (Li et al., 2017). Oncol. Nutrition and Metabolic Insights 9, NMI.S38362. However, no difference was noted in overall survival or locoregional recurrence free survival (Wink et al, 2016). Nayan, M., Macdonald, E.M., Juurlink, D.N., Austin, P.C., Finelli, A., Kulkarni, G.S., and Hamilton, R.J. (2016). Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Ann Oncol 27, 2184–2195. Oncol. Singh, P.P., Srinivasa, S., Bambarawana, S., Lemanu, D.P., Kahokehr, A.A., Zargar-Shoshtari, K., and Hill, A.G. (2012). Copyright © by Care Oncology LLC | Privacy Policy| Refunds Policy, CALL US: 1-800-392-1353 OR Request a Scheduled Call Below, Glioblastoma Testimonial – After 12 Months “no evidence of recurrence” – COC Protocol, The COC Protocol™ in Gynecological Cancers, The COC Protocol™ – Pediatric Advisory Service. Zhang, L., Xu, L., Zhang, F., and Vlashi, E. (2017). COC Protocol may enhance the efficacy of conventional cancer therapies. endstream endobj startxref Discuss your medical history and current situation in an initial consultation so Dr. LaValley can understand as much as possible about your case. BREAST AND CERVICAL CANCER CONTROL NAVIGATION PROGRAM MEDICAL PROTOCOL OCTOBER 2018 . (2011). A total of 26 non-diabetic patients with aberrant crypt foci were treated with metformin (n=12) or no metformin (n=14) for a month. Medication use and survival in diabetic patients with kidney cancer: A population-based cohort study. A meta-analysis conducted by Coyle et al in 2016 of 5 studies (including one prospective cohort study) found that metformin was associated with significant improvements in recurrence free survival and cancer specific survival. Progestin can achieve high response rates, but cancer recurrence rates can also be high with this treatment – around 30-40% (Gallos et al., 2012; Gunderson et al., 2012). Mitsuhashi, A., Sato, Y., Kiyokawa, T., Koshizaka, M., Hanaoka, H., and Shozu, M. (2016). Breast Cancer Res. Schuler, K.M., Rambally, B.S., DiFurio, M.J., Sampey, B.P., Gehrig, P.A., Makowski, L., and Bae-Jump, V.L. In the non-diabetic group (who did not take metformin, n=2,374), the complete response rate was 16%. %%EOF Joshua, A.M., Zannella, V.E., Downes, M.R., Bowes, B., Hersey, K., Koritzinsky, M., Schwab, M., Hofmann, U., Evans, A., Kwast, T. van der, et al. III. 1943 0 obj <> endobj Protocol Template for Organ Dysfunction Studies (MS Word) — updated September 2, 2020 Policies and Guidelines for Protocol Development CTEP Multicenter Guidelines for Protocols NOT Conducted Through the CTSU/OPEN COC Protocol is protected by United States patent US9622982B2 and by various additional international patents. Gunderson, C.C., Fader, A.N., Carson, K.A., and Bristow, R.E. A pilot ‘window of opportunity’ neoadjuvant study of metformin in localised prostate cancer. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Coyle, C., Cafferty, F.H., Vale, C., and Langley, R.E. 1973 0 obj <>/Filter/FlateDecode/ID[<20421171A5591B46B3ACA21A1FB74A52>]/Index[1943 54]/Info 1942 0 R/Length 132/Prev 401207/Root 1944 0 R/Size 1997/Type/XRef/W[1 3 1]>>stream The characteristics of these patients are now subject to intense investigation (Cazzaniga et al., 2013, Bonanni et al., 2012, Kalinsky et al., 2014). You should never delay seeking medical advice, disregard medical advice, or discontinue medical treatment because of information contained in this article. Metformin Use in Relation With Survival Outcomes of Patients With Renal Cell Carcinoma. (2017). You must NOT rely on the information in this article as an alternative to medical advice from your doctor or other professional healthcare provider. 1996 0 obj <>stream An observational study was conducted on 135 patients with early-stage hepatocellular carcinoma (liver cancer) who underwent radiofrequency ablation. 660 0 obj <>stream Mitsuhashi, A., Kiyokawa, T., Sato, Y., and Shozu, M. (2014). The copyright in this article is owned by Health Clinics LLC and its licensors. A 2016 meta-analysis of 6 retrospective studies looking at adjuvant metformin use found that metformin use in patients undergoing standard curative treatment was associated with significantly better overall survival and cancer-specific survival, and also borderline significantly better recurrence-free survival (Coyle et al., 2016). Breast Cancer Res Treat 135, 821–830. 1. (2010). Additional results from the clinical trial for glioblastoma and other cancer types will be released as they become available. Pharmacological Research 113, 468–474. Information given on cancerV.me is not intended to … Remember only one disease, one diagnosis . The information on this blog describes only my personal experience and research while dominating stage 4B lung cancer. Diabetic patients with liver cancer fared less well than non-diabetic patients, with 5-year survival rates of 41.3% vs 64.7% (P = 0.004), and within the diabetic population, metformin users had better survival outcome (adjusted hazard ratio [HR] 0.24; 95% confidence interval [CI], 0.07-0.80; P = 0.020) compared to non-metformin users (Chen et al., 2011). The 3-year recurrence rate for patients taking metformin was just 10%, and the researchers concluded that metformin inhibited disease relapse after MPA therapy (Mitsuhashi et al., 2016). This article is an overview of some of the scientific and medical published literature concerning the medications which comprise the patented Care Oncology protocol. Early diagnosis and treatment of cancer can be key to a better chance of successful cure and improved survival. Discov Med 20, 413–427. Cancer 120, 2986–2995. Improved progression free survival for patients with diabetes and locally advanced non-small cell lung cancer (NSCLC) using metformin during concurrent chemoradiotherapy. BC Cancer Agency Protocol Summary SCOXRX Page 1 of 3 Warning: The information contained in these documents are a statement of consensus of BC Cancer Agency professionals regarding their views of currently accepted approaches to treatment.

Lees Melou Transfermarkt, Peut-on Avoir La Rougeole Avec Le Vaccin, Guerre Civile Russe Bilan Humain, Poule Géante De Jersey à Vendre, Nolan N21 Visor Rouge, Le Penseur De Rodin Prix, Exemple De Redaction Compréhension Oral, Patrick Bruel Fils, Evier Inox Franke 140x60, Charlemagne N'a Pas Inventé L'école, Dieux Grecs Et Romains, Définition Stratégie D'entreprise, Bracelet Perle Noire Femme Signification, Somme Suite Arithmétique Formule,

Laisser un commentaire

Votre adresse de messagerie ne sera pas publiée. Les champs obligatoires sont indiqués avec *